Silicon nanoneedles physically deliver intact large DNA and CRISPR editing components together into plant cells, overcoming the delivery bottleneck that limits large-DNA genome engineering. Already validated for plasmids up to 22 kilobases, viral vectors, and sequence-confirmed gene knockouts across multiple plant species; the platform now targets 7–10 kb site-specific integration and scales toward larger payloads.
This silicon nanoneedle–based genome engineering platform addresses the delivery bottleneck that limits precise integration of large DNA sequences into crop genomes. Conventional plant transformation methods struggle to move large DNA molecules intact across the cell wall, restricting trait insertion. Nanoneedles physically penetrate plant cells with minimal damage, allowing the co-delivery of intact large DNA donor templates alongside genome-editing components — including CRISPR-Cas machinery — improving intracellular access for a wide range of cargo types.
The platform has delivered reporter plasmids, viral vectors, gene-silencing reagents, and CRISPR-Cas9 across several plant species and target tissues, including fluorescent reporter plots as large as 14 kb and viral vectors as large as 20 kb. This establishes a strong technical foundation for programmable, precise gene insertion in commercially important crops — a key capability for advanced breeding and trait stacking.
How it works:
Demonstrated capabilities:
Development path:
The platform is at technology readiness level 3–5 (laboratory/bench validation). Functional delivery and genome editing have been confirmed in multiple plant species, including sequence-validated knockout regeneration. Current research is extending the platform to additional crop species and target-defined integration, followed by validation of integration, fidelity, stable inheritance, and reproducibility — milestones required before field-level or commercial deployment.
The National University of Singapore is a comprehensive public research university and the country’s flagship, known for a global, collaborative culture. Industry partners access co‑located corporate labs, shared core facilities, and an integrated academic health system that supports clinical translation at scale. Campuses border the one‑north and Singapore Science Park innovation districts, linking companies to deep‑tech startups, government research institutes, and multinational R&D hubs. Research is powered by competitive national funding from the National Research Foundation Singapore, A*STAR, and the Ministry of Education, alongside international consortia and industry‑sponsored programs. A dedicated technology transfer office and enterprise programs handle IP, licensing, and venture creation, offering streamlined engagement models, pilots, and access to talent.